{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:58:05Z","timestamp":1772819885230,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118408","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T09:45:56Z","timestamp":1754646356000},"page":"118408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1047-2402","authenticated-orcid":false,"given":"Zhifang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-8874","authenticated-orcid":false,"given":"Anthony K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyambabu","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-In","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118408_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118408_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2025.118408_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118408_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","article-title":"Pancreatic cancer surveillance and survival of high-risk individuals","volume":"10","author":"Blackford","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118408_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118408_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-Mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100318","article-title":"Sequential first-line treatment with nab-paclitaxel\/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial","volume":"6","author":"Assenat","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118408_bib11","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: national cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2025.118408_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2025.118408_bib13","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at Dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2025.118408_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118408_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040419","article-title":"Oncolytic virotherapy for cancer: clinical experience","volume":"9","author":"Chaurasiya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118408_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans","volume":"115","author":"Cerullo","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118408_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.biopha.2025.118408_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12967-018-1483-x","article-title":"Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose","volume":"16","author":"O'Leary","year":"2018","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2025.118408_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omto.2018.03.001","article-title":"A novel oncolytic chimeric orthopoxvirus encoding luciferase enables Real-Time view of colorectal cancer cell infection","volume":"9","author":"O'Leary","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2025.118408_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.omto.2019.04.001","article-title":"A novel chimeric poxvirus encoding hNIS is Tumor-Tropic, imageable, and synergistic with radioiodine to sustain colon cancer regression","volume":"13","author":"Warner","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2025.118408_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jamcollsurg.2019.12.027","article-title":"Novel chimeric Immuno-Oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer","volume":"230","author":"Woo","year":"2020","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.biopha.2025.118408_bib22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41417-021-00350-4","article-title":"CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2025.118408_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2025.118408_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051354","article-title":"Intraperitoneal paclitaxel treatment for patients with pancreatic ductal adenocarcinoma with peritoneal dissemination provides a survival benefit","volume":"14","author":"Yamamoto","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118408_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","article-title":"Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies","volume":"243","author":"Koppe","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.biopha.2025.118408_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","article-title":"The pathology and genetics of metastatic pancreatic cancer","volume":"133","author":"Yachida","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006280","article-title":"Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases","volume":"11","author":"Yang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118408_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.omtm.2021.12.002","article-title":"A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer","volume":"24","author":"Chaurasiya","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2025.118408_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1160184","article-title":"Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer","volume":"5","author":"D'Alincourt Salazar","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.118408_bib30","article-title":"Anti-Tumor immunogenicity of the oncolytic virus CF33-hNIS-antiPDL1 against ex vivo peritoneal cells from gastric cancer patients","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118408_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013985","article-title":"Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL-37 treated monocytes","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118408_bib32","doi-asserted-by":"crossref","DOI":"10.3791\/57460","article-title":"Immunophenotyping of orthotopic homograft (Syngeneic) of murine primary KPC pancreatic ductal adenocarcinoma by flow cytometry","author":"An","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2025.118408_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-60327-321-3_4","article-title":"High-throughput quantitative bioluminescence imaging for assessing tumor burden","volume":"574","author":"Contero","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118408_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2144\/000112515","article-title":"Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals","volume":"43","author":"Klerk","year":"2007","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2025.118408_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: a delicate balance","volume":"9","author":"Schonrich","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.biopha.2025.118408_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094893","article-title":"Mechanisms of PD-L1 regulation in malignant and Virus-Infected cells","volume":"22","author":"Farrukh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118408_bib37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118408_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118408_bib39","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118408_bib40","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118408_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118408_bib42","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-04-0765","article-title":"Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model","volume":"10","author":"Tsai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118408_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061394","article-title":"Myxoma virus expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma","volume":"13","author":"Jazowiecka-Rakus","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118408_bib44","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118408_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003645","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial","volume":"9","author":"Moreno","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118408_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","article-title":"A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis","volume":"39","author":"Takahara","year":"2021","journal-title":"Invest N. Drug"},{"key":"10.1016\/j.biopha.2025.118408_bib47","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1080\/14796694.2024.2394013","article-title":"Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases","volume":"20","author":"Li","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2025.118408_bib48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10585-018-9925-7","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer","volume":"35","author":"Horvath","year":"2018","journal-title":"Clin. Exp. Metastas.."},{"key":"10.1016\/j.biopha.2025.118408_bib49","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-OT3-03-01","article-title":"Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer","volume":"83","author":"Yuan","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118408_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122043","article-title":"The feasibility of pressurised intraperitoneal aerosolised virotherapy (PIPAV) to administer oncolytic adenoviruses","volume":"13","author":"Tate","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500602X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500602X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:50:08Z","timestamp":1772797808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500602X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"alternative-id":["S075333222500602X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118408","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118408"}}